MARKET

DRNA

DRNA

Dicerna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.00
-0.51
-1.73%
Pre Market: 29.00 0 0.00% 07:23 03/04 EST
OPEN
29.50
PREV CLOSE
29.51
HIGH
29.90
LOW
28.20
VOLUME
5
TURNOVER
--
52 WEEK HIGH
29.90
52 WEEK LOW
11.75
MARKET CAP
2.21B
P/E (TTM)
-19.1104
1D
5D
1M
3M
1Y
5Y
Dicerna and Roche start mid-stage Hepatitis B RG6346 trial
Dicerna Pharmaceuticals (DRNA) announces that its development partner Roche (RHHBY) has initiated RG6346 in a Roche-sponsored Phase 2 combination trial for the treatment of chronic hepatitis B virus ((HBV)) infection.RG6346 is
Seekingalpha · 14m ago
The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2)
Benzinga · 1d ago
Carnival, Royal Caribbean, Switch and More Tuesday Afternoon Analyst Calls
247WallSt.com · 1d ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 2d ago
DJ Dicerna Pharmaceuticals Price Target Raised to $40.00/Share From $35.00 by HC Wainwright & Co.
Dow Jones · 2d ago
DJ Dicerna Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
8-K: Dicerna Pharmaceuticals Inc
(EDGAR Online via COMTEX) -- FALSE000139952900013995292021-03-022021-03-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
--Analyst Actions: HC Wainwright Adjusts Dicerna Pharmaceuticals PT to $40 From $35, Maintains Buy Rating
MT Newswires · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRNA. Analyze the recent business situations of Dicerna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DRNA stock price target is 37.38 with a high estimate of 45.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 279
Institutional Holdings: 72.95M
% Owned: 95.59%
Shares Outstanding: 76.32M
TypeInstitutionsShares
Increased
57
5.05M
New
54
2.50M
Decreased
65
4.79M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
Chairman/Independent Director
J. Kevin Buchi
President/Chief Executive Officer/Director
Douglas Fambrough
Chief Financial Officer
Douglas Pagan
Chief Operating Officer/Executive Vice President
James Weissman
Executive Vice President/Chief Scientific Officer
Bob Brown
Senior Vice President/Director of Human Resources
Regina Paglia
Vice President
Hardean Achneck
Executive Vice President
Shreeram Aradhye
Vice President
Steven Kates
Other
Robert Ciappenelli
Other
David Caponera
Secretary
Ling Zeng
Other
Rob Ciappenelli
Independent Director
Stephen Doberstein
Independent Director
Martin Freed
Other
Rebecca Peterson
Independent Director
Patrick Gray
Independent Director
Stephen Hoffman
Independent Director
.. ..
Independent Director
Adam Koppel
Independent Director
Marc Kozin
Independent Director
Anna Protopapas
Independent Director
Cynthia Smith
No Data
About DRNA
Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.

Webull offers kinds of Dicerna Pharmaceuticals Inc stock information, including NASDAQ:DRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRNA stock methods without spending real money on the virtual paper trading platform.